Mounjaro is more effective for weight loss than Ozempic: study reveals

November 27, 2023 09:22 AM PST | By Invezz
Follow us on Google News:

Mounjaro – a popular treatment for diabetes is more effective for losing weight than Ozempic, as per a large study of real-word data by Truveta Research.

FDA recently approved a new named Mounjaro

On Monday, the healthcare data analytics firm said patients on Mounjaro saw a bigger decline in their body weight after three, six, and twelve months compared to those on Ozempic. According to Dr Nick Stucky – its Vice President:

This study can help to inform patient care and outcomes today, not months from now.

The news arrives only days after FDA approved Zepbound – a new version of Mounjaro for weight loss. Eli Lilly & Co (NYSE: LLY) attributed $1.44 billion of revenue from “new products” in its latest reported quarter led by Mounjaro.

$LLY is currently up about 90% versus its year-to-date low. Watch here:

How does Mounjaro compare with Wegovy?

Neither Eli Lilly nor Novo Nordisk A/S (NYSE: NVO) – the company behind Ozempic have so far commented on the analysis of about 18,000 adults that showed Mounjaro to be three times more effective than its peer in reducing weight by 15%.  

Note that Lilly is comparing Mounjaro with a higher-dose variant of Ozempic known broadly as Wegovy as a treatment of obesity in a clinical trial results of which are expected in 2024.

Wegovy was a blockbuster drug for Novo Nordisk in its third financial quarter bringing in about $3.1 billion in revenue – more than double what Mounjaro generated for Eli Lilly in Q3.

Shares of Novo Nordisk have also gained close to 60% since early February.

The post Mounjaro is more effective for weight loss than Ozempic: study reveals appeared first on Invezz


The content, including but not limited to any articles, news, quotes, information, data, text, reports, ratings, opinions, images, photos, graphics, graphs, charts, animations and video (Content) is a service of Kalkine Media LLC (Kalkine Media, we or us) and is available for personal and non-commercial use only. The principal purpose of the Content is to educate and inform. The Content does not contain or imply any recommendation or opinion intended to influence your financial decisions and must not be relied upon by you as such. Some of the Content on this website may be sponsored/non-sponsored, as applicable, but is NOT a solicitation or recommendation to buy, sell or hold the stocks of the company(s) or engage in any investment activity under discussion. Kalkine Media is neither licensed nor qualified to provide investment advice through this platform. Users should make their own enquiries about any investments and Kalkine Media strongly suggests the users to seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice), as necessary. Kalkine Media hereby disclaims any and all the liabilities to any user for any direct, indirect, implied, punitive, special, incidental or other consequential damages arising from any use of the Content on this website, which is provided without warranties. The views expressed in the Content by the guests, if any, are their own and do not necessarily represent the views or opinions of Kalkine Media. Some of the images/music that may be used on this website are copyright to their respective owner(s). Kalkine Media does not claim ownership of any of the pictures/music displayed/used on this website unless stated otherwise. The images/music that may be used on this website are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source (public domain/CC0 status) to where it was found and indicated it, as necessary.

Top Listed Companies